FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Fiche publication
Date publication
mai 2019
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier, Pr GHIRINGHELLI François
Tous les auteurs :
Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J
Lien Pubmed
Résumé
Epidermal growth factor receptor (EGFR) and hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathways, which promote tumour growth and proliferation, are often deregulated in advanced gastroesophageal adenocarcinomas. We assessed whether adding panitumumab (an EGFR inhibitor) or rilotumumab (a HGF inhibitor) to first-line fluoropyrimidine-based and platinum-based chemotherapy (modified oxaliplatin, leucovorin and fluorouracil [mFOLFOX6]) benefits to patients with advanced gastroesophageal adenocarcinoma.
Mots clés
Advanced gastroesophageal adenocarcinoma, First-line treatment, Panitumumab, Rilotumumab, mFOLFOX6
Référence
Eur. J. Cancer. 2019 May 23;115:97-106